Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jennifer Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap

Blood (2021) 138 (Supplement 1): 312.

https://doi.org/10.1182/blood-2021-147972

Published: 2021

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD

Blood (2018) 132 (Supplement 1): 457.

https://doi.org/10.1182/blood-2018-99-110128

Published: 2018

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

Journal Articles

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Blood (2014) 124 (21): 519.

https://doi.org/10.1182/blood.V124.21.519.519

Published: 2014

Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD

Blood (2014) 124 (21): 2161.

https://doi.org/10.1182/blood.V124.21.2161.2161

Published: 2014

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Ronjon Chakraverty, MD, Nilusha Manji, BSc, Richard Clark, MD, Charles Crawley, MD, Peter Johnson, MD, Effie Liakopoulou, MD, Judith Marsh, MD, Donald Milligan, MD, Emma Morris, MD, Karl Peggs, MD, Kirsty Thomson, MD, John Snowden, MD, Graham Jackson, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1055.

https://doi.org/10.1182/blood.V110.11.1055.1055

Published: 2007

Journal Articles

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Nicholas Heaney, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, Jane Tighe, Lorna McLintock, Timothy Hughes, Tessa L. Holyoake

Blood (2007) 110 (11): 1033.

https://doi.org/10.1182/blood.V110.11.1033.1033

Published: 2007

Journal Articles

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, Donald Small

Blood (2006) 108 (10): 3262–3270.

https://doi.org/10.1182/blood-2006-04-015560

Published: 2006

Journal Articles

Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party.

Christoph Schmid, MD, Anja v. Biezen, Kimmo Porkka, MD, Yves Chalandon, MD, Alvaro Urbano, MD, Eduardo Olavarria, MD, Theo de Witte, MD, Bernd Hertenstein, MD, Wiliam Archese, MD, Richard Clark, MD, Hans-Jochem Kolb, MD, Dietger Niederwieser, MD, Cesare Guglielmi, MD

Blood (2005) 106 (11): 704.

https://doi.org/10.1182/blood.V106.11.704.704

Published: 2005

Journal Articles

Frequency of Blast Crisis after Achieving Complete Cytogenetic Remission in First Chronic Phase CML Patients Who Recieved Imatinib Therapy within Six Months of Diagnosis.

Arian Laurence, David Marin, Richard Clark, Patricia Shepherd4, Stephen Mackinnon

Blood (2004) 104 (11): 1021.

https://doi.org/10.1182/blood.V104.11.1021.1021

Published: 2004

Journal Articles

A Phase II Trial of the FLT3 Inhibitor CEP701 as First Line Treatment for Older Patients with Acute Myeloid Leukaemia Not Considered Fit for Intensive Chemotherapy.

Steven Knapper, Alan K. Burnett, Jonathan Kell, Raj Chopra, Richard Clark, Jenny Craig, Dominic Culligan, Mark J. Levis, Nigel H. Russell, Donald Small

Blood (2004) 104 (11): 864.

https://doi.org/10.1182/blood.V104.11.864.864

Published: 2004

NARROW

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party.

Frequency of Blast Crisis after Achieving Complete Cytogenetic Remission in First Chronic Phase CML Patients Who Recieved Imatinib Therapy within Six Months of Diagnosis.

A Phase II Trial of the FLT3 Inhibitor CEP701 as First Line Treatment for Older Patients with Acute Myeloid Leukaemia Not Considered Fit for Intensive Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only